The Week In Biopharma, June 27 – July 1
Contract Development and Manufacturing (CDMO)
- StimLabs, LLC. Announces Growing Portfolio with New Product: Enverse™ (USA)
- FDA clears LiveMetric’s smartwatch-like, cuffless blood pressure sensor (Luxembourg)
- Eurofins DiscoverX Opens Shanghai Office (China)
- Lonza to Build Large-Scale Commercial Fill/Finish Facility in Stein (Switzerland)
- Evolved By Nature Raises $120M Series C, Led by Teachers’ Venture Growth, to Scale Sustainable Activated Silk™ Technology for Global Impact (USA)
- Croda Pharma Expands Lipid Systems Capability to Support mRNA Vaccines (UK)
- WuXi STA Opens High-Potency API Plant (China)
- Clarius Introduces Partnership with ImaCor That Powers New FDA Cleared Handheld Hemodynamic Ultrasound (Canada/USA)
- Visby Medical’s VC round swells to $135M to add new tests to hand-held PCR platform (USA)
- Charles River Labs Opens Plasmid DNA CoE in Cheshire, (UK)
- EQT Private Equity Acquires SPT Labtech from Battery Ventures (UK)
- TruDiagnostic partners with HealthyLongevityglobal to offer Biological Age testing in broader worldwide markets (USA)
- Batavia Biosciences plans new facility to jump into commercial manufacturing game (The Netherlands)
- Schrödinger to kick off first human trial of its computer-designed blood cancer drug (USA)
- Shimadzu Scientific Instruments Extends HQ Campus (Japan)
- Vetter’s Newest Clinical Manufacturing Site Completes First Customer Fills (Germany)
- PicnicHealth feasts on $60M funding round to grow its patient data programs (USA)
- Cue Health to lay off 170 workers due to ‘economic challenges,’ COVID test funding cuts (USA)
- CoreRx Expands Capabilities (USA
Biopharma
- Heron, Avadel Slash Headcount, Brace for Economic Downturn (USA, Ireland)
- Faeth Therapeutics raises $47 million to advance clinical trials and feed the fight against cancer (USA)
- Inhibrx Announces Completion of Phase 1 Combination Dose Escalation for INBRX-105, a Novel Targeted 4-1BB Agonist, and Draws an Additional $60 Million from Oxford Finance (USA)
- Ardelyx Announces $20 Million Financing Agreement with HealthCare Royalty Partners (USA)
- Inceptor Bio Announces Strategic Collaboration with University of Minnesota to Develop Novel iPSC Platform for the Advancement of Next-Generation Allogeneic Cell Therapies (USA)
- Phanes Therapeutics’ PT886 granted Orphan Drug Designation for the treatment of pancreatic cancer by the FDA (USA)
- Oyster Point Laying Off 50 with Focus on Dry Eye Drug Launch (USA)
- Bolden Therapeutics Receives $497,500 SBIR Grant From The National Institute On Aging To Support Development Of Antisense Oligonucleotides To Promote Neurogenesis (USA)
- Tryp Therapeutics Strengthens IP Portfolio with Provisional Patent Application for Binge Eating Disorder Treatment (Canada)
- Generian and Astellas Enter into Collaboration and Exclusive License Agreement to Discover and Develop Novel Small Molecules For Undruggable Targets (USA/Japan)
- ReCode breaks the mold with $120M financing, bringing clutch of Big Pharmas along for ride (USA)
- Chasing AnaptysBio and Lilly, MiroBio rounds up $97M for autoimmune checkpoint agonist clinical trials (UK)
- Bayer opens $140M cancer research center, adds 50 jobs in hopes of becoming top oncology company (Germany)
- Novartis Reveals Restructure will Cost up to 8,000 Jobs (USA)
- Chemomab Awarded New U.S. Patent for CM-101, Its First-in-Class CCL24 Neutralizing Antibody (Israel)
- BioLineRx Announces Collaboration Agreement with GenFleet Therapeutics to Further Develop Motixafortide in Pancreatic Ductal Adenocarcinoma (PDAC) (Israel/China)
- Palleon Pharmaceuticals and Henlius Enter into Strategic Collaboration to Develop Bifunctional Sialidase Therapies (USA/China)
- Xenpozyme® (olipudase alfa) approved by European Commission as first and only treatment for ASMD (France)
- Nexviadyme® (avalglucosidase alfa) approved by European Commission as a potential new standard of care for the treatment of Pompe Disease (France)
- Astellas and Sutro Biopharma Announce Worldwide Strategic Collaboration to Advance Novel Immunostimulatory Antibody-Drug Conjugates (iADCs) (Japan/USA)
- Astellas’ gene therapy strategy faces fresh setback as FDA puts Pompe disease med on hold (Japan)
- Ipsen to acquire Epizyme, expanding its portfolio in oncology (France)
- US FDA Approves Prestige Biopharma’s IND for Phase 1/2a Trial of First-in-Class Pancreatic Cancer Treatment, PBP1510 (Singapore)
- Gates Foundation Funds Phase Genomics a company Cataloging the Viruses that Infect Bacteria (USA)
Artificial Intelligence
- ColubrisMX, Inc. Announces Corporate Rebranding to ENDOQUEST Robotics™ (USA)
